10x Genomics (TXG) reported $151.65 million in revenue for the quarter ended September 2024, representing a year-over-year decline of 1.3%. EPS of -$0.30 for the same period compares to -$0.51 a year ago. The reported revenue represents a surprise of +0.02% over the Zacks Consensus Estimate of $151.62 million. With the consensus EPS estimate being -$0.34, the EPS surprise was +11.76%. While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to ...